<i>In Vitro</i>
            Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of
            <i>Mycobacterium abscessus</i>

Kaushik, Amit; Ammerman, Nicole C.; Martins, Olumide; Parrish, Nicole; Nuermberger, Eric L.

doi:10.1128/aac.00470-19

Cited by 85 publications

(71 citation statements)

References 27 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-eight clinical isolates of MABC were collected at Johns Hopkins Hospital, Baltimore, MD, USA, from 2005 to 2015 and were described previously (8,10,18). M. abscessus ATCC 19977 T was purchased from the American Type Culture Collection (Manassas, VA, USA) and used as a reference strain.…”

Section: Nct03630094mentioning

confidence: 99%

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

Kaushik

Ammerman

Parrish

et al. 2019

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the in vitro activity of β-lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other β-lactams, similar to prior results with avibactam and relebactam.

show abstract

Section: Nct03630094mentioning

confidence: 99%

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

Kaushik

Ammerman

Parrish

et al. 2019

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…It remains unlikely that these findings would be not entirely dependent on source control processes. Future research should be directed to investigate ERV in non–FDA‐approved indications, particularly Neisseria gonorrhea , and nontuberculous mycobacterium species . To the best of our knowledge, no future upcoming studies of ERV in other indications are in preclinical development.…”

Section: Place In Therapymentioning

confidence: 99%

“…Future research should be directed to investigate ERV in non-FDA-approved indications, particularly Neisseria gonorrhea, and nontuberculous mycobacterium species. 56 To the best of our knowledge, no future upcoming studies of ERV in other indications are in preclinical development. Additionally, because oral options for MDR gramnegative infections are limited, revisiting oral ERV, if possible, would highly impact its place in therapy.…”

Section: Place In Therapymentioning

confidence: 99%

Evaluation of Eravacycline: A Novel Fluorocycline

et al. 2020

View full text Add to dashboard Cite

Eravacycline (ERV), formerly known as TP‐434, is a novel tetracycline (TET) antibiotic that exhibits in vitro activity against various gram‐positive, gram‐negative aerobic and anaerobic pathogens, including those exhibiting TET‐specific acquired resistance mechanisms. Similar to other TETs, it inhibits protein synthesis through binding to the 30S ribosomal subunit. Eravacycline was approved by the United States Food and Drug Administration (FDA) in August 2018 for the treatment of complicated intraabdominal infections (cIAIs) in adults following the Investigating Gram‐Negative Infections Treated with Eravacycline (IGNITE)1 and IGNITE4 phase III trials. In these two, double‐blind, multicenter clinical trials, ERV was proven noninferior in terms of clinical response in comparison to ertapenem and meropenem, respectively. Eravacycline was well tolerated with nausea, vomiting, and infusion site reactions being the most commonly reported adverse reactions. Clinicians now have ERV as a novel therapeutic option for the treatment of adults with intraabdominal infections, allergies to β‐lactam agents, Clostridioides difficile‐associated diarrhea, or if tolerability to other agents is a concern.

show abstract

“…Omadacycline (PO/IV), Eravacycline (PO/IV) omadacycline [32,33] and eravacycline [34,35] have activity against reference and clinical strains N/A Report of one patient-noted clinical improvement [36] Tedizolid (PO/IV)…”

Section: N/amentioning

confidence: 99%

Alternative and Experimental Therapies of Mycobacterium abscessus Infections

Meir

Barkan

2020

IJMS

View full text Add to dashboard Cite

Mycobacterium abscessus is a non-tuberculous mycobacterium notoriously known for causing severe, chronic infections. Treatment of these infections is challenging due to either intrinsic or acquired resistance of M. abscessus to multiple antibiotics. Despite prolonged poly-antimicrobial therapy, treatment of M. abscessus infections often fails, leading to progressive morbidity and eventual mortality. Great research efforts are invested in finding new therapeutic options for M. abscessus. Clofazimine and rifabutin are known anti-mycobacterial antibiotics, repurposed for use against M. abscessus. Novel antimicrobials active against M. abscessus include delamanid, pretomanid and PIPD1 and the recently approved beta-lactamase inhibitors avibactam, relebactam and vaborbactam. Previously unused antimicrobial combinations, e.g. vancomycin–clarithromycin and dual beta-lactam therapy, have been shown to have synergistic effect against M. abscessus in experimental models, suggesting their possible use in multiple-drug regimens. Finally, engineered phage therapy has been reported to be clinically successful in a severe case of disseminated M. abscessus infection. While many of these experimental therapeutics have shown activity against M. abscessus in vitro, as well as in intracellular and/or animal models, most have little if any evidence of effect in human infections. Clinical studies of M. abscesssus treatments are needed to reliably determine the value of their incorporation in therapeutic regimens.

show abstract

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

Cited by 85 publications

References 27 publications

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

Evaluation of Eravacycline: A Novel Fluorocycline

Alternative and Experimental Therapies of Mycobacterium abscessus Infections

Contact Info

Product

Resources

About